tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Atossa Therapeutics reports Q2 EPS (7c), consensus (6c)
PremiumThe FlyAtossa Therapeutics reports Q2 EPS (7c), consensus (6c)
12d ago
Optimistic Buy Rating for Atossa Therapeutics Driven by Promising Developments and Strong Financial Health
Premium
Ratings
Optimistic Buy Rating for Atossa Therapeutics Driven by Promising Developments and Strong Financial Health
25d ago
Positive FDA Feedback and Strategic Advancements Boost Atossa Therapeutics’ Clinical Outlook
Premium
Ratings
Positive FDA Feedback and Strategic Advancements Boost Atossa Therapeutics’ Clinical Outlook
26d ago
Atossa Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
PremiumRatingsAtossa Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
3M ago
Atossa Therapeutics reports results from Phase 2 EOP sub-study
Premium
The Fly
Atossa Therapeutics reports results from Phase 2 EOP sub-study
3M ago
Optimistic Buy Rating for Atossa Therapeutics Driven by Strategic Focus on Z-endoxifen and Strong Financial Position
Premium
Ratings
Optimistic Buy Rating for Atossa Therapeutics Driven by Strategic Focus on Z-endoxifen and Strong Financial Position
3M ago
Atossa Therapeutics and Nona Biosciences partner in breast cancer antibodies
PremiumThe FlyAtossa Therapeutics and Nona Biosciences partner in breast cancer antibodies
5M ago
Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress
Premium
Company Announcements
Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress
5M ago
Strategic Advancements and Promising Clinical Data Drive Buy Rating for Atossa Therapeutics
Premium
Ratings
Strategic Advancements and Promising Clinical Data Drive Buy Rating for Atossa Therapeutics
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100